摘要
目的探讨一组免疫组化指标包括CK5/6、calretinin、WT1、HBME-1、CD141、Ber-EP4、Moc-31、AE1/AE3、B72.3、EMA、CEAv、imentin在恶性胸膜间皮瘤与肺腺癌鉴别诊断中的作用。方法采用免疫组化EnVision二步法检测16例恶性胸膜间皮瘤和32例肺腺癌中CK5/6、calretinin、WT1、HBME-1、CD141、Ber-EP4、Moc-31、AE1/AE3、B72.3、EMA、CEAv、imentin的表达情况。结果calretinin、CD141、WT1、CK5/6、EMA、Ber-EP4、B72.3、CEA、AE1/AE3和vimentin在恶性胸膜间皮瘤和肺腺癌中的表达差异显著(P<0.05),HBME-1和Moc-31的表达差异不显著;间皮瘤最敏感的抗体是CD141、Vim和AE1/AE3,其次是HBME-1、WT-1、calretinin、EMA和CK5/6,而特异性最高的抗体是calretinin,其次为CD141、WT-1和CK5/6。在肺腺癌中,敏感性最高的抗体是AE1/AE3(100%),其次是EMA、CEA和B72.3;特异性最高的抗体是CEA和B72.3,其次是Ber-EP4。结论CD141c、alretinin、WT-1v、imentin、CEA和B72.3一组抗体兼具特异性和敏感性,可作为恶性间皮瘤和肺腺癌鉴别诊断中的首选抗体。
Objective To investigate the value of a panel of immunohistochemical markers comprising CK5/6, Calrefinin, WT1, HBME-1, CD141, Ber-EP4, Moe-31, AE1/AE3, B72.3, EMA, CEA and vimentin in the differential diagnosis between malignant pleural mesothelioma and pulmonary adenocarcinoma. Methods The expression of the above biomarkers was detected in 16 cases of malignant pleural mesothelioma and 32 cases of pulmonary adenocarcinoma by immunochemical EnVision method. Results There was a significant difference in expression of calretinin, CD141, WT1, CK5/6, EMA, Ber-EP4, B72.3, CEA, AE1/AE3 and vimetin between malignant pleural mesothelioma and pulmonary adenocarcinoma （ P 〈 0.05）; but the expression of HBME-1, Moc-31 between them was not significant （ P 〉 0.05） ; the most sensitive antibody to malignant pleural mesothelioma was CD141, vimentin and AE1/AE3, followed by HBME-1, WT-1, calretinin, EMA and CK5/6; the most sepecific antibody to malignant pleural mesothelioma was calretinin （ 100% ）, followed by CD141, WT-1 and CK5/6; the most sensitive antibody to pulmonary adenocarcinoma was AE1/AE3 （100%）, followed by EMA, CEA, B72.3; the most specific antibody to pulmonary adenocarcinoma were CEA and 1372.3, followed by Ber-EP4. Conclusion A panel of antibodies including CD141, Calretinin, WT-1, vimentin, CEA and B72.3 with a high combined sensitivity and specificity can be used as primary antibodies for distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
出处
《诊断病理学杂志》
CSCD
2008年第6期471-474,共4页
Chinese Journal of Diagnostic Pathology
关键词
胸膜肿瘤
恶性间皮瘤
腺癌
免疫组化
诊断
鉴别
Pleural neoplasms
Malignant mesothehoma
Adenocarcinoma
Immunochemistry
Diagnosis, differentialtion
